A phase II trial of dacomitinib, an oral pan-human EGF receptor (HER) inhibitor, as first-line treatment in recurrent and/or metastatic squamous-cell carcinoma of the head and neck
Journal article published in 2013 by
A. R. Abdul Razak,
D. Soulières,
S. A. Laurie 
,
S. J. Hotte,
S. Singh,
E. Winquist,
S. Chia,
C. Le Tourneau,
P.-F. Nguyen-Tan,
E. X. Chen,
K. K. Chan,
T. Wang,
N. Giri,
C. Mormont,
S. Quinn
and other authors.
,
S. J. Hotte,
S. Singh,
E. Winquist,
S. Chia,
C. Le Tourneau,
P.-F. Nguyen-Tan,
E. X. Chen,
K. K. Chan,
T. Wang,
N. Giri,
C. Mormont,
S. Quinn
and other authors.
This paper is available in a repository.
Full text: Download
Published version:
archiving forbidden
Data provided by 